Fig. 1

Galantamine prevents massive splenomegaly in chronically treated FMF-KI mice. A FMF-KI mice were treated with an escalated dose of galantamine (4–12 mg/kg) or PBS twice daily for ~ 8 weeks starting at age 1.5 weeks (upper panel). The lower panels include representative images of FMF-KI mouse spleens harvested at the end of treatment compared with wildtype (WT) spleen (weights: PBS = 330 mg; gal = 70 mg; WT = 90 mg). B Spleen weights (mg) from galantamine-, huperzine A-, and PBS-treated FMF-KI mice compared with WT. FMF-KI mice were treated with huperzine A (1 mg/kg twice daily) for 4–5 weeks starting at the age of ~ 4 weeks and compared to the control group in the galantamine vs. PBS experiment (first column). (Data presented as mean ± SEM; *P < 0.025 by Mann–Whitney U test with Bonferroni correction). C Body weights (g) of galantamine- and PBS-treated FMF-KI mice at the end of treatment period. In all figures, wild type measurements are included for comparison only